image
Arbutus Biopharma Corporation ABUS
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 3.005
-6.97 %
$ 575 M
Market Cap
-7.91
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ABUS stock under the worst case scenario is HIDDEN Compared to the current market price of 3 USD, Arbutus Biopharma Corporation is HIDDEN

ABUS Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ABUS stock under the base case scenario is HIDDEN Compared to the current market price of 3 USD, Arbutus Biopharma Corporation is HIDDEN

ABUS Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ABUS stock under the best case scenario is HIDDEN Compared to the current market price of 3 USD, Arbutus Biopharma Corporation is HIDDEN

ABUS Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart ABUS

image
1M -9%
6M -37%
1Y 10%
3Y 17%
5Y 157%
All
$4.2$4.2$4.0$4.0$3.8$3.8$3.6$3.6$3.4$3.4$3.2$3.2$3.0$3.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
6.17 M REVENUE
-65.98%
Growth Rates
1Year -65.98%
3Years -17.50%
5Years 0.53%
7Years -7.56%
10Years -8.50%
-76.3 M OPERATING INCOME
2.28%
Growth Rates
1Year 2.28%
3Years -1.25%
5Years 11.93%
7Years 5.20%
10Years -8.75%
-69.9 M NET INCOME
4.02%
Growth Rates
1Year 4.02%
3Years 2.85%
5Years 14.58%
7Years 2.65%
10Years -6.06%
-64.8 M OPERATING CASH FLOW
24.54%
Growth Rates
1Year 24.54%
3Years 1.34%
5Years 1.80%
7Years -4.21%
10Years -17.97%
22.9 M INVESTING CASH FLOW
-54.80%
Growth Rates
1Year -54.80%
3Years 56.19%
5Years -4.13%
7Years -2.70%
10Years 9.74%
52 M FINANCING CASH FLOW
69.66%
Growth Rates
1Year 69.66%
3Years -27.64%
5Years 6.78%
7Years 0.76%
10Years -1.53%
1.57 M REVENUE
17.55%
Growth Rates
1Year -65.98%
3Years -17.50%
5Years 0.53%
7Years -7.56%
10Years -8.50%
-13.9 M OPERATING INCOME
35.01%
Growth Rates
1Year 2.28%
3Years -1.25%
5Years 11.93%
7Years 5.20%
10Years -8.75%
-12.5 M NET INCOME
36.44%
Growth Rates
1Year 4.02%
3Years 2.85%
5Years 14.58%
7Years 2.65%
10Years -6.06%
-10.3 M OPERATING CASH FLOW
50.26%
Growth Rates
1Year 24.54%
3Years 1.34%
5Years 1.80%
7Years -4.21%
10Years -17.97%
13.4 M INVESTING CASH FLOW
211.89%
Growth Rates
1Year -54.80%
3Years 56.19%
5Years -4.13%
7Years -2.70%
10Years 9.74%
1.42 M FINANCING CASH FLOW
-19.94%
Growth Rates
1Year 69.66%
3Years -27.64%
5Years 6.78%
7Years 0.76%
10Years -1.53%
Balance Sheet Arbutus Biopharma Corporation
image
Current Assets 127 M
Cash & Short-Term Investments 123 M
Receivables 2.41 M
Other Current Assets 2.28 M
Non-Current Assets 4.39 M
Long-Term Investments 0
PP&E 4.36 M
Other Non-Current Assets 34 K
93.10 %3.31 %Total Assets$131.7m
Current Liabilities 15.6 M
Accounts Payable 2.32 M
Short-Term Debt 483 K
Other Current Liabilities 12.8 M
Non-Current Liabilities 18.7 M
Long-Term Debt 806 K
Other Non-Current Liabilities 17.9 M
6.74 %37.33 %52.17 %Total Liabilities$34.3m
EFFICIENCY
Earnings Waterfall Arbutus Biopharma Corporation
image
Revenue 6.17 M
Cost Of Revenue 0
Gross Profit 6.17 M
Operating Expenses 82.5 M
Operating Income -76.3 M
Other Expenses -6.4 M
Net Income -69.9 M
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)6m06m(82m)(76m)6m(70m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
Averages
1Year 100.00%
3Years -36.64%
5Years -122.52%
7Years -336.03%
10Years -693.19%
-1236.74% OPERATING MARGIN
-1236.74%
Averages
1Year -1236.74%
3Years -611.67%
5Years -668.04%
7Years -1037.01%
10Years -4148.02%
-1133.04% NET MARGIN
-1133.04%
Averages
1Year -1133.04%
3Years -570.87%
5Years -671.95%
7Years -983.56%
10Years -3352.61%
-71.81% ROE
-71.81%
Averages
1Year -71.81%
3Years -63.76%
5Years -60.18%
7Years -77.25%
10Years -78.73%
-53.09% ROA
-53.09%
Averages
1Year -53.09%
3Years -46.36%
5Years -44.90%
7Years -56.46%
10Years -57.86%
-65.47% ROIC
-65.47%
Averages
1Year -65.47%
3Years -57.38%
5Years -51.33%
7Years -61.47%
10Years -62.55%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Arbutus Biopharma Corporation
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)(90m)(90m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -69.9 M
Depreciation & Amortization 1.38 M
Capital Expenditures 0
Stock-Based Compensation 8.99 M
Change in Working Capital -2.83 M
Others -1.96 M
Free Cash Flow -64.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Arbutus Biopharma Corporation
image
ABUS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership Arbutus Biopharma Corporation
image
Sold
0-3 MONTHS
252 K USD 4
3-6 MONTHS
0 USD 0
6-9 MONTHS
32.6 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 2 weeks ago
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? Here is how Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year. zacks.com - 2 weeks ago
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago. zacks.com - 3 weeks ago
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending globenewswire.com - 3 weeks ago
GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster*, reproducible supplemental screening and streamline exam readings on patients with dense breasts. Approximately 71% of cancers occur in dense breasts.1 According to studies across the U.S. and Europe, 40% of women2 and 70% of Asian women3 have dense brea. businesswire.com - 1 month ago
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries. globenewswire.com - 1 month ago
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries. globenewswire.com - 1 month ago
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D. globenewswire.com - 1 month ago
Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr. Chris DeMuth, Jr. shares some of his current top picks. Arbutus Biopharma is a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID-19 vaccine technology. seekingalpha.com - 2 months ago
Arbutus Provides 2025 Corporate and Financial Update Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon globenewswire.com - 3 months ago
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development Company's phase 2a trial of Imdusiran with pegylated interferon alfa-2a achieved a functional cure in 25% of Hepatitis B patients. The company is developing its own in-house oral PD-L1 inhibitor, AB-101, with preliminary data expected in the first half of 2025. The global Hepatitis B Virus market size is anticipated to reach $6.65 billion by 2034. seekingalpha.com - 3 months ago
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will participate in the virtual H.C Wainwright @ Home fireside chat series taking place on Tuesday, December 3, 2024 at 11:00 am ET. globenewswire.com - 4 months ago
8. Profile Summary

Arbutus Biopharma Corporation ABUS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 575 M
Dividend Yield 0.00%
Description Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Contact 701 Veterans Circle, Warminster, PA, 18974 https://www.arbutusbio.com
IPO Date July 26, 2007
Employees 44
Officers Ms. Shannon Briscoe SPHR Vice President of Human Resources Ms. Lisa M. Caperelli Vice President of Investor Relations Mr. Tuan Nguyen Chief Financial Officer Ms. Lindsay Androski J.D., M.B.A. President, Chief Executive Officer & Chairman Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C. Corporate Secretary